Scholar Rock (NASDAQ:SRRK) Director Sells 5,446 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 5,446 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the sale, the director directly owned 34,301 shares of the company’s stock, valued at approximately $1,848,137.88. This represents a 13.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded up $0.48 during mid-day trading on Monday, reaching $55.36. 1,182,357 shares of the company traded hands, compared to its average volume of 1,407,918. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $56.54. The firm has a market cap of $6.63 billion, a PE ratio of -15.42 and a beta of 0.67. The company’s 50 day moving average price is $48.43 and its 200-day moving average price is $46.59.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the prior year, the firm earned ($0.67) earnings per share. On average, equities analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Canaccord Genuity Group began coverage on shares of Scholar Rock in a research note on Monday, April 20th. They set a “buy” rating and a $62.00 price objective for the company. Barclays boosted their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. HC Wainwright boosted their price objective on shares of Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Finally, Wedbush raised their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $56.00.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently bought and sold shares of SRRK. IFP Advisors Inc increased its position in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Scholar Rock during the 4th quarter worth approximately $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock in the fourth quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its holdings in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Scholar Rock in the 4th quarter valued at about $44,000. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).